3-Year Follow-up of Chemotherapy Following Radium-223 Dichloride (Ra-223) in Castration-Resistant Prostate Cancer (CRPC) Patients (Pts) With Symptomatic Bone Metastases (Mets) From ALSYMPCA

被引：0
|
作者：
Koenig, E. [1 ]
Sartor, O. [2 ]
Coleman, R. E. [3 ]
Nilsson, S. [4 ]
Voyelzang, N. [5 ]
Staudacher, K. [6 ]
Thuresson, M. [7 ]
Parker, C. [8 ,9 ]
机构：
[1] Outpatient Clin Urol, Berlin, Germany
[2] Tulane Canc Ctr, New Orleans, LA USA
[3] Univ Sheffield, Weston Pk Hosp, Sheffield, S Yorkshire, England
[4] Karolinska Univ Hosp, Stockholm, Sweden
[5] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
[6] Bayer AS, Oslo, Norway
[7] Statisticon AB, Uppsala, Sweden
[8] Royal Marsden NHS Fdn Trust, Sutton, Grossbritannien, England
[9] Inst Canc Res, Sutton, Grossbritannien, England
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
0099
引用
收藏
页码：86 / 86
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety of radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases who did or did not receive prior docetaxel (D) in the phase III ALSYMPCA trial
    Vogelzang, Nicholas J.
    Helle, Svein Inge
    Johannessen, Dag Clement
    O'Sullivan, Joe M.
    Garcia-Vargas, Jose E.
    O'Bryan-Tear, C. Gillies
    Shan, Minghua
    Parker, Chris
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [42] Updated analysis of radium-223 dichloride (Ra-223) impact on skeletal-related events (SRE) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase III randomized trial (ALSYMPCA)
    Vogelzang, Nicholas J.
    Parker, Chris
    Nilsson, Sten
    Coleman, Robert Edward
    O'Bryan-Tear, C. Gillies
    Shan, Minghua
    Sartor, A. Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [43] ESTIMATING THE ECONOMIC IMPACT OF RADIUM RA 223 DICHLORIDE (RADIUM-223) IN TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER (CRPC) WITH SYMPTOMATIC BONE METASTASES AND NO KNOWN VISCERAL METASTATIC DISEASE
    Valderrama, A.
    Bilir, S. P.
    Wehler, E. A.
    Seal, B. S.
    Wen, L.
    Yaldo, A.
    Munakata, J.
    VALUE IN HEALTH, 2014, 17 (03) : A74 - A74
  • [44] Hematotoxicityand non-hematological adverse events of Ra-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases
    Ahmadzadehfar, H.
    Azgomi, K.
    Rogenhofer, S.
    Bundschuh, R.
    Kuerpig, S.
    Thomas, L.
    Essler, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S738 - S739
  • [45] Safety of radium-223 dichloride (Ra-223) with docetaxel (D) in patients with bone metastases from castration-resistant prostate cancer (CRPC): A phase I Prostate Cancer Clinical Trials Consortium Study
    Morris, Michael J.
    Hammers, Hans J.
    Sweeney, Christopher
    Antonarakis, Emmanuel S.
    Cho, Steve Y.
    Pandit-Taskar, Neeta
    Jacene, Heather
    Bloma, Marianne
    Aksnes, Anne-Kirsti
    O'Bryan-Tear, C. Gillies
    Carrasquillo, Jorge A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [46] Radium-223 Dichloride: A Novel Treatment Option for Castration-Resistant Prostate Cancer Patients With Symptomatic Bone Metastases
    McGann, Shane
    Horton, Evan R.
    ANNALS OF PHARMACOTHERAPY, 2015, 49 (04) : 469 - 476
  • [47] Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases
    Uemura, Hirotsugu
    Uemura, Hiroji
    Nagamori, Satsohi
    Wakumoto, Yoshiaki
    Kimura, Go
    Kikukawa, Hiroaki
    Yokomizo, Akira
    Mizokami, Atsushi
    Kosaka, Takeo
    Masumori, Naoya
    Kawasaki, Yoshihide
    Yonese, Junji
    Nasu, Yasutomo
    Fukasawa, Satoshi
    Sugiyama, Takayuki
    Kinuya, Seigo
    Hosono, Makoto
    Yamaguchi, Iku
    Akagawa, Takashi
    Matsubara, Nobuaki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2019, 24 (05) : 557 - 566
  • [48] Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases
    Hirotsugu Uemura
    Hiroji Uemura
    Satsohi Nagamori
    Yoshiaki Wakumoto
    Go Kimura
    Hiroaki Kikukawa
    Akira Yokomizo
    Atsushi Mizokami
    Takeo Kosaka
    Naoya Masumori
    Yoshihide Kawasaki
    Junji Yonese
    Yasutomo Nasu
    Satoshi Fukasawa
    Takayuki Sugiyama
    Seigo Kinuya
    Makoto Hosono
    Iku Yamaguchi
    Takashi Akagawa
    Nobuaki Matsubara
    International Journal of Clinical Oncology, 2019, 24 : 557 - 566
  • [49] Radium-223 Dichloride: A Review of Its Use in Patients with Castration-Resistant Prostate Cancer with Symptomatic Bone Metastases
    Matt Shirley
    Paul L. McCormack
    Drugs, 2014, 74 : 579 - 586
  • [50] Radium-223 Dichloride: A Review of Its Use in Patients with Castration-Resistant Prostate Cancer with Symptomatic Bone Metastases
    Shirley, Matt
    McCormack, Paul L.
    DRUGS, 2014, 74 (05) : 579 - 586
12345